A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer
Conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Interventions: Biological: Amivantamab; Biological: Pembrolizumab; Drug: Paclitaxel Sponsors: Janssen Research& Development, LLC Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | HNSCC | Research | Skin Cancer | Squamous Cell Carcinoma | Study